Driven to solve medicine’s toughest problems. We are Serinus Bio. 

Our values.

  1. Patients first, data second.

  2. Biology is complex. We love that.

  3. It didn’t work? Try again!

  4. Rigorous science builds a rigorous company.

Team.

Maxwell Sherman

Co-Founder & CTO

Adam Yaari

Co-Founder & CEO

  • Prior to founding Serinus, Max spent over 13 years at the intersection of medicine, biology and mathematics at top research institutions. He has devoted his career to developing novel tools and treatments for underserved patient populations.

    Max received his PhD in computational biology from MIT, masters in mathematics from the University of Cambridge, and BS in applied mathematics & biology from Brown University. He is the recipient of multiple national and international research awards, and his work has been published in top journals, including Science, Nature Biotechnology and Nature Neuroscience.

    fun fact: Max began his medical journey by spending 5 years in the back of an ambulance.

    Twitter — Linkedin

  • Prior to founding Serinus, Adam held numerous leadership positions in the private and non-profit sectors including as both a Microsoft Fellow and Fellow at Flagship Pioneering. With over 10 years of entrepreneurship experience, Adam is passionate about developing advanced AI models for biological research that will bring medicine to scale.

    Adam received his PhD and MS in computer science from MIT, MSc in computer science and mathematics from the Weizmann Institute of Science, and dual major BSc in computer science and neuroscience from Bar-Ilan University.

    Fun fact: before his academic trajectory Adam served as a Navy elite unit team commander.

    Twitter — Linkedin

Eduardo Farias

Director of Biology

Tyler Earnest

Staff ML Engineer

  • Prior to joining Serinus Bio Eduardo served as a Professor at Icahn School of Medicine at Mount Sinai and a founding team member at HiberCell. With over 35 years of cancer research experience, Eduardo has seen two compounds from early discovery to Phase 2 clinical trials, published numerous papers in top-tier journals, and participated in several NIH/NCI and DoD review panels and study sections.

    Eduardo specializes in cancer metastasis, minimal residual disease, tumor dormancy, stress biology, epigenetic reprogramming, and complex preclinical systems.

    He received his PhD from the University of Buenos Aires, Argentina, where his thesis was selected for the Best Thesis on Basic Sciences Award.

    Fun fact: Eduardo began his academic journey as an oceanologist diving with whales.

    Linkedin

  • Prior to joining Serinus Bio, Tyler spent five years designing, prototyping, and deploying machine learning algorithms to glean valuable insights from real-world clinical data at SimBioSys and PathAI. Inspired by personal experiences with cancer, Tyler's passion lies in enhancing patient outcomes using his broad skillset of software engineering, physics and biology.

    Tyler received his PhD in physics from the University of Illinois at Urbana-Champaign and a dual BS in chemistry and physics from the South Dakota School of Mines and Technology. Prior to leaving academia, he served as a postdoctoral fellow at the National Center for Supercomputing Applications.

    Fun fact: Tyler lived on an alligator farm until he was 10 years old. Fortunately, he still has all his fingers.

    Linkedin

  • Prior to joining Serinus Bio, Oliver spent over five years at the intersection of biology and computation. Starting out in the wet-lab, Oliver contributed to several research projects ranging from optimizing nanoparticle drug delivery vehicles to understanding anti-microbial resistance in bacteria. Realizing that he was better with his hands on a keyboard, Oliver transitioned to computational research to uncover novel cancer drivers with deep learning in the Berger Lab at MIT. More recently, Oliver has developed cutting-edge somatic CNV detection algorithms at The Broad Institute in the Getz lab.

    Oliver graduated Phi Beta Kappa from the University of Pennsylvania, where he double majored in Biophysics and Computer Science.

    Fun Fact: Oliver was once trapped in Antarctica for 4 extra days on an expedition, nearly running out of supplies.

  • Prior to joining Serinus Bio, Lee spent 18 years in high-performance computing and data analysis with a focus on cancer research and medicine, including large-scale novel epigenomic analysis pipelines at the NIH, pediatric cancer genomics at Children’s Hospital of Philadelphia, and circulating tumor DNA and immunogenomics scientific collaborations at Personalis.

    Lee received his MD from Georgetown University, pre-medical studies at the University of Pennsylvania, attended pediatrics residency at Duke, and received both his MSE and BS in computer science from Johns Hopkins University. His extensive research work has been published in journals such as Nature, Cancer Research, and Nucleic Acids Research.

    Fun fact: In his free time, Lee supports homeless communities by delivering concurrent technology classes.

    Linkedin

Francisco Guedes

Research Scientist

Lee McDaniel

Director of Bioinformatics

Oliver Priebe

Bioinformatics Scientist

Scientific Co-Founders.

Trey Ideker

Scientific Co-Founder

Bonnie Berger

Technical Co-Founder

  • Trey Ideker is a Professor of Medicine, Bioengineering and Computer Science at the University of California, San Diego. A world leader in systems and network biology, Trey has pioneered the use of machine learning to build mechanistic models of cancer and other human diseases. He directs or co-directs the National Resource for Network Biology, and the Cancer Cell Map and Psychiatric Cell Map Initiatives. His work has appeared in publications such as Nature, Science, and Cell and has been cited >92K times.

  • Bonnie Berger is the Simons Professor of Mathematics at MIT. She is a foundational pioneer of computational molecular biology, having contributed widely to nearly every domain of genomics. She and her students have fundamentally advanced structure-based protein determination, drug-target and target-target interaction prediction, and genome sequence analysis. She is the recipient of the distinguished ISCB Senior Scientist Award and an elected member of the American Academy of Arts and Sciences.

Scientific Advisory Board.

Eliezer Van Allen

Scientific Advisor

William Hahn

Scientific Advisor

  • William Hahn is the William Rosenberg Professor of Medicine in the Department of Medical Oncology at Dana-Farber Cancer Institute and Harvard Medical School, an Institute Member of the Broad Institute, and Executive Vice President and the Chief Operating Officer at the Dana-Farber Cancer Institute. Dr. Hahn and his lab have pioneered functional genomic approaches to identify and validate cancer targets. These tools are now used worldwide to discover and validate molecularly targeted cancer therapies.

  • Eliezer Van Allen is the Chief of the Division of Population Sciences at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. His lab advances precision oncology using new techniques in molecular biology and machine learning to study resistance and metastasis mechanisms. His research fundamentally shaped understanding of resistance to Raf inhibitors and immunotherapy, leading to improved treatment responses in otherwise refractory patients.

CAREERS

Want to help us build a world where every cancer patient has a safe and effective treatment option?

We are looking for passionate scientists, researchers and engineers who want to use technology to revolutionize oncology.